Search Results
Your search for The ASCO Post matches 17639 pages
Showing 9001 - 9050Has the Promise of Precision Medicine Been Oversold?
Recently, the term “personalized medicine” in oncology care has been overtaken by the more contemporary concept of “precision medicine.” According to the National Research Council of the National Academies of Science, Engineering, and Medicine, the newer terminology shifts the focus to improving...
Overcoming Long-Term Health and Economic Impact of Cancer on Young Adult Survivors
A pair of studies showcased the potentially devastating long-term health and financial consequences cancer has on adult survivors of childhood cancer compared with other adults, as well as survival disparities based on health insurance status.1,2 Despite increasing survival rates among the more...
AMA Awards Research Grants to Honor Women in Medicine
Each September, the American Medical Association (AMA) recognizes influential female physician leaders in honor of Women in Medicine Month. To showcase the accomplishments of these leaders, the AMA Women Physicians Section (WPS) and the AMA Foundation announced the winners of the 2018 Joan F....
Nicholas D. James, PhD, MBBS, on Prostate Cancer: Updates From the STAMPEDE Trial
Nicholas D. James, PhD, MBBS, of University Hospitals Birmingham NHS Trust, discusses study findings on treating metastatic castration-sensitive prostate cancer, including results on radiotherapy and abiraterone (Abstract LBA5_PR).
Tony Mok, MD, on NSCLC: Targeted Treatment Update
Tony Mok, MD, of the Chinese University of Hong Kong, discusses two important studies in non–small cell lung cancer: FLAURA, which looked at the first-line activity of osimertinib and the mechanisms of resistance; and ALESIA, which examined crizotinib dosing.
Suresh S. Ramalingam, MD, on Lung Cancer: Research Highlights
Suresh S. Ramalingam, MD, of the Emory University School of Medicine, summarizes the top-line lung cancer results reported at this year’s ESMO Congress, including the role of targeted treatment for early stage NSCLC, combining immunotherapy for surgically resectable disease, and immunotherapy for...
Laurence Albiges, MD, PhD, on RCC: Challenging Established Front-Line Treatment
Laurence Albiges, MD, PhD, of Gustave Roussy, discusses data from the global, phase III JAVELIN trial that compared axitinib plus avelumab vs sunitinib, which could lead to a new standard of care in renal cell carcinoma (Abstract LBA6_PR).
ESMO 2018: Survival Results From STAMPEDE: Local Radiotherapy in Newly Diagnosed Metastatic Prostate Cancer With Low Disease Burden
Radiotherapy to the prostate improved overall survival in men newly diagnosed with metastatic prostate cancer who have a low metastatic disease burden, but not in those with higher burden of disease, according to results from a preplanned analysis of a large comparison study reported by Parker et...
ESMO 2018: JAVELIN Renal 101: Avelumab Plus Axitinib in Previously Untreated Renal Cell Carcinoma
A combination of the immune checkpoint blocker avelumab (Bavencio) plus the tyrosine kinase inhibitor axitinib (Inlyta) improved progression-free survival (PFS) in previously untreated patients with advanced renal cell carcinoma (RCC) in the phase III JAVELIN Renal 101 study, according to results...
ESMO 2018: SOLO-1: Olaparib Maintenance Extends Progression-Free Survival in BRCA1/2-Mutated Advanced Ovarian Cancer
Two-year maintenance therapy with olaparib (Lynparza), a poly ADP-ribose polymerase (PARP) inhibitor, led to a substantial improvement in progression-free survival (PFS) in newly diagnosed patients with advanced ovarian cancer and a BRCA1/2 mutation, results from the phase III SOLO-1 trial...
New Vice-Chairs for SU2C Scientific Advisory Committee Announced
Three new Vice-Chairs of the Scientific Advisory Committee of Stand Up To Cancer (SU2C) were announced by the American Association for Cancer Research (AACR), the Scientific Partner of SU2C. They are Nobel Laureate Elizabeth H. Blackburn, PhD, of the University of California San Francisco;...
Subha Madhavan, PhD, Named Chief Data Scientist at Georgetown University Medical Center
Georgetown University Medical Center has named Subha Madhavan, PhD, as its Chief Data Scientist and Director of its Office for Health Data Science and Informatics. Dr. Madhavan, Associate Professor in the Department of Oncology, also serves as Director of the Innovation Center for Biomedical...
Cancer Moonshot Awards Grant to Roswell Park
Through a grant provided by the Cancer Moonshot, Roswell Park Comprehensive Cancer Center will be able to support and advance various new cancer research projects, including the development of a Data Management and Resource-Sharing Center to serve the Immuno-Oncology Translational Network (IOTN)....
Arul Chinnaiyan, MD, PhD, Granted NCI Award to Investigate Cancer Genomics
Arul Chinnaiyan, MD, PhD, of the University of Michigan Rogel Cancer Center, has received an Outstanding Investigator Award from the National Cancer Institute (NCI) that provides $6.5 million in funding over 7 years. The grant will fund research to create new bioinformatics resources and identify...
NIH Grants Funding to Collaboration for Genomic Research Program
The National Institutes of Health (NIH) recently awarded inaugural funding to the genetic testing firm Color, in partnership with the Broad Institute of the Massachusetts Institute of Technology and Harvard, and the Laboratory for Molecular Medicine at Partners HealthCare, to establish one of three ...
Three Scientists Recognized With Awards for Distinguished Research in Tumor Immunology
The Cancer Research Institute honored three scientists for their work in immunology and cancer immunotherapy at the group’s annual gala held recently in New York. Padmanee Sharma, MD, PhD, Professor of Genitourinary Medical Oncology and Immunology at The University of Texas MD Anderson Cancer...
Talazoparib Approved for BRCA-Mutated, HER2-Negative Breast Cancer
On October 16, 2018, the U.S. Food and Drug Administration approved talazoparib (Talzenna), a poly (ADP-ribose) polymerase (PARP) inhibitor, for patients with deleterious or suspected deleterious germline BRCA-mutated, HER2-negative locally advanced or metastatic breast cancer. Patients must be...
Labeling Act to Keep Drug Label Information Up-to-Date Introduced to Senate
Friends of Cancer Research (Friends) recognized Senators Orrin Hatch (R–UT) and Michael Bennet (D–CO) for responding to a recently identified public health issue and proposing a solution to an issue impacting patients and their physicians. Senators Hatch and Bennet jointly introduced the Making...
Françoise Mornex, MD, PhD, Honored With IASLC Distinguished Award
Françoise Mornex, MD, PhD, was recognized by the International Association for the Study of Lung Cancer (IASLC) with a Distinguished Award at the IASLC 19th World Conference on Lung Cancer (WCLC) in Toronto, Canada. Dr. Mornex is Professor of Oncology at the University Claude Bernard in Lyon,...
FDA Awards Research Grants in Development of Treatments of Rare Diseases, Cancers
The U.S. Food and Drug Administration (FDA) has announced that it has awarded 12 new clinical trial research grants totaling more than $18 million over the next 4 years to enhance the development of medical products for patients with rare diseases. These new grants were awarded to principal...
Assay Uses Big Data to Predict Responses to Immunotherapy
In the age of big data, cancer researchers are discovering new ways to monitor the effectiveness of immunotherapy treatments. Researchers at the Johns Hopkins Bloomberg~Kimmel Institute for Cancer Immunotherapy developed a new way to use bioinformatics as a gathering tool to determine how a...
Nancy Berliner, MD, Named Next Editor-in-Chief of Blood
The American Society of Hematology (ASH) has selected Nancy Berliner, MD, the H. Franklin Bunn Professor of Medicine and Chief of Hematology at Brigham and Women’s Hospital and Professor of Medicine at Harvard Medical School, as the next Editor-in-Chief of its journal Blood. Dr. Berliner was...
Ignacio I. Wistuba, MD, Receives IASLC Pathology/Translation Research Award
Oncologist and Professor Ignacio I. Wistuba, MD, of The University of Texas MD Anderson Cancer Center, has been recognized by the International Association for the Study of Lung Cancer (IASLC) with a Distinguished Award at the IASLC 19th World Conference on Lung Cancer (WCLC) in Toronto. Dr....
Nise Yamaguchi, MD, PhD, Honored With IASLC Lifetime Scientific Achievement Award
São Paulo oncologist and immunologist, Nise Yamaguchi, MD, PhD, has been recognized by the International Association for the Study of Lung Cancer (IASLC) with a Distinguished Award at the IASLC 19th World Conference on Lung Cancer (WCLC) in Toronto. Dr. Yamaguchi was given the Joseph W. Cullen...
Cabozantinib in Advanced Hepatocellular Cancer: Call for Revision of Practice Standards
As reported in The New England Journal of Medicine by Ghassan K. Abou-Alfa, MD, and colleagues, and reviewed in this issue of The ASCO Post, the phase III CELESTIAL trial has demonstrated that cabozantinib (Cabometyx) improved the median overall survival to 10.2 months in comparison to 8 months...
Fadlo R. Khuri, MD, FACP, Acknowledged With IASLC Lifetime Scientific Achievement Award
Oncologist, physician, and Professor, Fadlo R. Khuri, MD, FACP, has been recognized by the International Association for the Study of Lung Cancer (IASLC) with a Distinguished Award at the IASLC 19th World Conference on Lung Cancer (WCLC) in Toronto. Dr. Khuri received the Joseph W. Cullen...
Jean-Charles Soria, MD, PhD, Receives 2018 ESMO Award
The European Society for medical oncology (ESMO) has granted the 2018 ESMO Award to Jean-Charles Soria, MD, PhD, an international lung cancer expert and pioneer in the development of anticancer drugs. The award was founded in 1985 to acknowledge an ESMO member who has made contributions to the...
Sibylle Loibl, MD, PhD, on Metastatic Breast Cancer: Research Highlights
Sibylle Lobil, MD, PhD, of the German Breast Group, discusses findings in metastatic breast cancer from the IMpassion130 trial in triple-negative disease and from the PALOMA3 and SOLAR-1 trials in hormone receptor–positive, HER2-negative disease (Abstracts LBA1_PR, LBA2_PR, LBA3_PR).
Lisa A. Carey, MD, and Sherene Loi, MD, PhD, on TNBC: Combination Immune Checkpoint Inhibitor Therapy
Lisa A. Carey, MD, of the University of North Carolina, and Sherene Loi, MD, PhD, of the Peter MacCallum Cancer Centre, discuss the phase III IMpassion 130 trial testing the first-line combination of the PD-L1 inhibitor atezolizumab plus nab-paclitaxel in metastatic triple-negative breast cancer...
ESMO 2018: SOLAR-1: Alpelisib in Patients With PIK3CA-Mutated HR-Positive, HER2-Negative Advanced Breast Cancer
Targeting a common mutation in patients with hormone receptor (HR)–positive, human epidermal growth factor receptor 2 (HER2)-negative advanced breast cancer with the alpha-specific phosphatidylinositol-3-kinase (PI3K) inhibitor alpelisib improved progression-free survival, according to...
ESMO 2018: PALOMA-3: Palbociclib in Hormone Receptor–Positive, HER2-Negative Advanced Breast Cancer
Treatment with the cyclin-dependent kinase (CDK) 4/6 inhibitor palbociclib (Ibrance) achieved a clinically meaningful improvement in overall survival in patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced breast cancer that has relapsed or ...
ESMO 2018: IMpassion 130: Atezolizumab Plus Nab-Paclitaxel in Metastatic Triple-Negative Breast Cancer
A combination of immunotherapy and chemotherapy improves survival in some patients with metastatic triple-negative breast cancer, according to late-breaking results from the IMpassion130 trial reported by Schmid et al at the European Society for Medical Oncology (ESMO) 2018 Congress (Abstract...
ESMO 2018: HDAC Inhibitor Therapy in Advanced Hormone Receptor–Positive Breast Cancer
A phase III trial presented by Jiang et al at the European Society for Medical Oncology (ESMO) 2018 Congress showed activity of histone deacetylase (HDAC) inhibitor therapy in advanced hormone receptor–positive breast cancer (Abstract 283O_PR). Endocrine therapies are the foundation of...
Cora N. Sternberg, MD, on Renal and Bladder Cancers: Focus on Immunotherapy
Cora N. Sternberg, MD, of San Camillo-Forlanini Hospital and the Israel Englander Institute of Precision Medicine at Weill Cornell, discusses results from the phase III CheckMate-025 study on nivolumab vs everolimus for mRCC; the CheckMate-214 study on nivolumab, ipilimumab, and sunitinib for...
Sibylle Loibl, MD, PhD, on Metastatic Breast Cancer: Research Highlights
Sibylle Lobil, MD, PhD, of the German Breast Group, discusses findings in metastatic breast cancer from the IMpower 130 trial in triple-negative disease and from the PALOMA3 and SOLAR-1 trials in hormone receptor–positive, HER2-negative disease.
Karl Lewis, MD, on Basal Cell Carcinoma: An Ongoing Study
Karl Lewis, MD, of the University of Colorado, discusses a phase II study of cemiplimab in patients with advanced basal cell carcinoma who experienced progression of disease on, or were intolerant of, prior hedgehog pathway inhibitor therapy.For more information about this ongoing trial, visit...
Eileen M. O’Reilly, MD, on Hepatobiliary Cancer: Multimodality Approaches
Eileen M. O’Reilly, MD, of Memorial Sloan Kettering Cancer Center, discusses the latest information on locoregional and systemic treatments of hepatocellular carcinoma as well as targeted therapy for biliary cancer.
Ronald de Wit, MD, PhD, on Bladder Cancer: Results From KEYNOTE-057
Ronald de Wit, MD, PhD, of the University Medical Center Rotterdam, discusses phase II findings on the efficacy of pembrolizumab in bacillus Calmette-Guérin–unresponsive bladder cancer with high risk for disease progression.
Jeffrey S. Weber, MD, PhD, on Discontinuing Immunotherapy: When Is the Right Time?
Jeffrey S. Weber, MD, PhD, of the NYU Langone Perlmutter Cancer Center, discusses how long people with melanoma should be treated with PD-1 blockade and the data on remission rates.
Johan F. Vansteenkiste, MD, PhD, on NSCLC: Immunotherapy and Targeted Treatments
Johan F. Vansteenkiste, MD, PhD, of Catholic University Leuven, summarizes a session he co-chaired that included discussion of translating advances in stage IV disease to nonmetastatic lung cancer, TKI approaches in early-stage disease, and integrating immunotherapy and TKIs in stage III disease...
Martin Reck, MD, PhD, on Immunotherapy for Thoracic Malignancies: Expert Perspective
Martin Reck, MD, PhD, of the LungenClinic, discusses recent updates on biomarkers beyond PD-L1 expression; mechanisms and management of resistance; as well as combinations and novel approaches in lung cancer.
Ezra E.W. Cohen, MD, on Head and Neck Cancer: Using Curative Immunotherapy
Ezra E.W. Cohen, MD, of the University of California, San Diego, discusses the effectiveness of anti–PD-1 therapy in patients with recurrent head and neck cancer and the studies that might help predict who will benefit, how to combine agents, and ways to reduce long-term toxicity.
Matti S. Aapro, MD, on Advanced Disease: Reducing Use of Futile Treatments
Matti S. Aapro, MD, of the Genolier Cancer Centre, discusses the challenges of avoiding futile treatments and the need to work with patients, integrate palliative care, and monitor toxicities.
Matti S. Aapro, MD, on Immunotherapy in Older Patients
Matti S. Aapro, MD, of the Genolier Cancer Centre, discusses the optimal treatment and supportive care for older patients with cancer, including the importance of maintaining dose density and intensity as well as monitoring toxicity.
Matthew J. Ellis, MB, BChir, PhD, on Breast Cancer: Neoadjuvant Endocrine Therapy
Matthew J. Ellis, MB, BChir, PhD, of the Baylor College of Medicine, discusses data on endocrine therapy alone or in combination with targeted treatments for postmenopausal women with strongly ER-positive/HER2-negative tumors.
Alexander M.M. Eggermont, MD, PhD, on Melanoma: Advances in Adjuvant Therapy
Alexander M.M. Eggermont, MD, PhD, of Gustave Roussy, discusses findings from recent adjuvant trials in high-risk melanoma, and what the NCCN Guidelines recommend in light of such data as results on dabrafenib plus trametinib vs anti–PD-1 treatments (nivolumab or pembrolizumab) and the new standard ...
Margaret Foti, PhD, MD (hc), Receives 2018 ESMO Women for Oncology Award
The European Society for Medical Oncology (ESMO) has recognized Margaret Foti, PhD, MD (hc), with the 2018 ESMO Women for Oncology Award. The award recognizes an ESMO member who has contributed to supporting the career development of women in oncology. The recipient must have actively worked to...
Cancer Care in the Palestinian Territories
The global burden of cancer is huge and growing. In 2018, there will be > 18 million new cancer cases and 9.6 million deaths.1,2 Although several recent articles have reviewed cancer in developing countries, few have focused on the Palestinian territories. There are several reasons for that,...
How the Nobel Prize Could Spur More Cancer Advances
Even before James P. Allison, PhD, made an appearance at the Fourth International Cancer Immunotherapy Conference: Translating Science Into Survival in New York City, the excitement among attendees was palpable. Earlier that day, October 1, 2018, Dr. Allison and Tasuku Honjo, MD, PhD, of Kyoto...
Paolo A. Ascierto, MD, on Melanoma: Acute and Chronic Toxicities
Paolo A. Ascierto, MD, of Istituto Nazionale Tumori–Fondazione Pascale, discusses the breakthroughs in melanoma treatment and the challenges of managing toxicities, especially endocrine and neurologic side effects, which can require lifetime hormone replacement and may cause permanent dysfunction.
